Hera Biotech
Women's health biotech building non-invasive, tissue-based diagnostics for endometriosis and cervical cancer.
Hera Biotech develops non-invasive, tissue-based diagnostics for endometriosis and cervical cancer, built for OB-GYN, fertility and drug discovery work. Its MetriDx test detects and stages endometriosis, and its HERAfem device is a point-of-care cervical cancer diagnostic. The company is led by President and CEO Somer Baburek and has offices in the USA, Mexico and Switzerland.
Details
- Industry
- Biotechnology and women's health diagnostics
- Founded
- 2020
- Ownership
- Women led
Services
MetriDx (opens in a new tab)
Non-invasive molecular test for endometriosis detection and staging.
HERAfem (opens in a new tab)
Non-invasive, point-of-care cervical cancer diagnostic device.